Professor Ranjeny Thomas is an NHMRC Research Fellow recognized as an international leader in the field of antigen-specific tolerance in rheumatoid arthritis (RA). During the last 5 years, she reported the first clinical trial of antigen-specific dendritic cell therapy in RA, and attracted investment from the US-based Johnson and Johnson group of companies into Dendright, a start-up company commercialising immunotherapy for RA co-invented and patented by Thomas. If fully realized, this work will be transformative for human health in the next decade. Her research leadership is demonstrable in 2 successful program grant awards as CIA and 2 investigator-driven translational clinical trials.